FORT WORTH, Texas, May 8, 2025 /PRNewswire/ -- PHX MINERALS INC., "PHX" or the "Company" (NYSE: PHX), today reported financial and operating results for the quarter ended March 31, 2025.

Summary of Results for the Quarter Ended March 31, 2025

Net income was $4.4 million, or $0.12 per diluted share, compared to net income of $0.1 million, or $0.00 per diluted share, for the quarter ended Dec. 31, 2024, and net loss of ($0.2) million, or ($0.01) per diluted share, for the quarter ended March 31, 2024.Adjusted EBITDA(1) was $6.2 million, compared to $5.4 million for the quarter ended Dec. 31, 2024 and $4.6 million for the quarter ended March 31, 2024.Royalty production volumes decreased 9% to 1,910 Mmcfe compared to the quarter ended Dec. 31, 2024, and increased 3% compared to the quarter ended March 31, 2024.Total production volumes decreased 9% to 2,159 Mmcfe compared to the quarter ended Dec. 31, 2024, and increased 2% compared to the quarter ended March 31, 2024.Converted 65 gross (0.113 net) wells to producing status, compared to a conversion of 71 gross (0.22 net) wells to producing status during the quarter ended Dec. 31, 2024 and 85 gross (0.32 net) during the quarter ended March 31, 2024.Inventory of 247 gross (1.017 net) wells in progress and permits as of March 31, 2025, compared to 225 gross (0.91 net) wells in progress and permits as of Dec. 31, 2024 and 230 gross (1.099 net) wells in progress and permits as of March 31, 2024.Total debt was $19.8 million, down $9.8 million since Dec. 31, 2024, and the debt-to-adjusted EBITDA (TTM) (1) ratio was 0.86x at March 31, 2025.

Raises Fiscal 2025 Outlook

LAKEWOOD, Colo., May 8, 2025 /PRNewswire/ -- Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) today announced results for its second quarter of fiscal 2025 ended March 31, 2025.

Highlights for Second Quarter Fiscal 2025 Compared to Second Quarter Fiscal 2024

Net sales increased 9.0% to $335.8 million;Daily average comparable store sales increased 8.9%, and accelerated to 16.4% on a two-year basis;Net income increased 64.6% to $13.1 million, with diluted earnings per share of $0.56;Adjusted EBITDA increased 33.3% to $26.3 million; andOpened two new stores.

WASHINGTON, May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025.

Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA. We continue to see a very strong selling environment and we achieved significant organic growth with five new revenue agreements announced today. Operationally, we continue scaling our innovative oncology condition management solution to help Evolent further impact specialty care member experience, costs and outcomes. Performance Suite margins, including leading indicators on utilization, and AI-based automation initiatives, like Auth Intel, are both currently tracking favorably. From an innovation perspective we remain focused on improving member and provider experience in specialty care, while continuing to manage affordability for the system – a combination we believe Evolent is uniquely positioned to deliver. In the time ahead we'll remain disciplined in capital allocation, prioritizing cash generation and debt paydown. I am proud of our recent progress and I believe that our strong pipeline, low market penetration, innovative product stack and highly engaged team of 4,500 professionals, positions Evolent to deliver sustained value to our shareholders, partners and members in the short and long term."

Net sales of $280.5 million, an increase of 17 percent compared with the fourth quarter of 2024Net income of $1.3 million and adjusted EBITDA(1) of $17.7 millionInvested $27.5 million in capital expenditures and deployed $5.6 million to repurchase common sharesCash and cash equivalents balance was $180.3 million with total liquidity(2) of $432.0 million as of March 31, 2025

CANTON, Ohio, May 8, 2025 /PRNewswire/ -- Metallus (NYSE: MTUS), a leader in high-quality specialty metals, manufactured components and supply chain solutions, today reported first-quarter 2025 net sales of $280.5 million and net income of $1.3 million, or $0.03 per diluted share. On an adjusted basis(1), the first-quarter 2025 net income was $3.2 million, or $0.07 per diluted share, and adjusted EBITDA was $17.7 million.

BETHESDA, Md., May 8, 2025 /PRNewswire/ -- Saul Centers, Inc. (NYSE: BFS), an equity real estate investment trust ("REIT"), announced operating results for the quarter ended March 31, 2025 ("2025 Quarter").  Total revenue for the 2025 Quarter increased to $71.9 million from $66.7 million for the quarter ended March 31, 2024 ("2024 Quarter").  Net income decreased to $12.8 million for the 2025 Quarter from $18.3 million for the 2024 Quarter. During the 2025 Quarter, the Company continued to lease residential units and work on retail spaces at Twinbrook Quarter Phase I.  As of May 5, 2025, 274 residential units have been leased and occupied. 

NEW YORK, May 8, 2025 /PRNewswire/ -- OUTFRONT Media Inc. (NYSE: OUT) announced today that its board of directors has declared a quarterly cash dividend on the Company's common stock of $0.30 per share payable on June 30, 2025, to shareholders of record at the close of business on June 6, 2025.

About OUTFRONT Media Inc.OUTFRONT leverages the power of technology, location, and creativity to connect brands with consumers outside of their homes through one of the largest and most diverse sets of billboard and transit assets in the United States. Through its technology platform, OUTFRONT will fundamentally change the ways advertisers engage audiences on-the-go.

Revenues of $390.7 million

Operating income of $13.9 million

 Net loss attributable to OUTFRONT Media Inc. of $20.6 million

Adjusted OIBDA of $64.2 million

AFFO attributable to OUTFRONT Media Inc. of $23.9 million

Quarterly dividend of $0.30 per share, payable June 30, 2025

NEW YORK, May 8, 2025 /PRNewswire/ -- OUTFRONT Media Inc. (NYSE: OUT) today reported results for the quarter ended March 31, 2025.

Revenue in Q1 Grew 28.7% YoY and Organic Revenue Grew 14.6% YoY Quarterly Market Share Grew 125bps YoY to a Record 6.0%; Organic Share Was Up 82bpsOperating Cash Flow Grew 169% YoY to a Record $23.1 Million in Q1

NEW YORK, May 8, 2025 /PRNewswire/ -- Compass, Inc. (NYSE: COMP) ("Compass" or "the Company"), a leading tech-enabled real estate services company that includes the largest residential real estate brokerage in the United States by sales volume1, announced its financial results for the first quarter ended March 31, 2025.

NORTH BETHESDA, Md., May 8, 2025 /PRNewswire/ -- Federal Realty Investment Trust (NYSE:FRT) today reported its results for the first quarter ended March 31, 2025. For the three months ended March 31, 2025 and 2024, net income available for common shareholders was $0.72 per diluted share and $0.66 per diluted share, respectively. Operating income for the same periods was $108.1 million and $100.2 million, respectively.

Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%

ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the first quarter ended March 31, 2025.

First Quarter 2025 Highlights

Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million

ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025.

Recent Highlights

Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565 million to $585 millionOwned 21 aircraft as of March 31, 2025Announced strategic plan to open design center of excellence and new disposables manufacturing facility in Mirandola, ItalyHosted annual symposium at the International Society of Heart and Lung Transplantation (ISHLT) 45th Annual Meeting & Scientific Session in Boston; highlighted latest design and potential sample size of upcoming next-gen clinical programs10 abstracts and presentations at ISHLT featured OCS™ & NOP™ clinical value

NEW YORK, May 8, 2025 /PRNewswire/ -- Omnicom (NYSE: OMC) today announced that it will present at the J.P. Morgan 53rd Annual Global Technology, Media and Communications Conference in Boston, Massachusetts on Wednesday, May 14, 2025 at 10:00 a.m. Eastern Time. Live and archived webcasts will be available at the investor relations section of www.omnicomgroup.com.

About Omnicom

Omnicom (NYSE: OMC) is a leading provider of data-inspired, creative marketing and sales solutions. Omnicom's iconic agency brands are home to the industry's most innovative communications specialists who are focused on driving intelligent business outcomes for their clients. The company offers a wide range of services in advertising, strategic media planning and buying, precision marketing, retail and digital commerce, branding, experiential, public relations, healthcare marketing and other specialty marketing services to over 5,000 clients in more than 70 countries. For more information, visit www.omnicomgroup.com.

Reports 23 Percent Increase in ARR to $20.4 Million and 43 Net New Platform Deployments, Positive Net Income and Record Adjusted EBITDA and Cashflow

HENDERSON, Nev., May 8, 2025 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), the leading AI-powered research workflow platform, reported financial results for its fiscal third quarter ended March 31, 2025.

Fiscal Third Quarter 2025 Summary

MORRISTOWN, N.J., May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, today announced financial results for the first quarter ended March 31, 2025, and provided recent corporate progress.

"By uniting novel approaches to tumor targeting with next wave technologies, our goal at Whitehawk Therapeutics is to efficiently deliver improved ADC therapies for patients with difficult-to-treat cancers. In the first quarter of 2025, we made meaningful progress in advancing our portfolio toward the clinic and remain on track to bring all three assets to IND by mid-2026, with the first IND filed in Q4 this year," said Dave Lennon, President and CEO of Whitehawk Therapeutics. "Our assets target PTK7, MUC16 and SEZ6 – which we believe have the potential for broad clinical impact comparable to well-established targets like HER2 and TROP2, but with less competition and greater opportunity for differentiation. Coupled with our TOPO1-based leading next wave platform, we are confident in the strength of our strategy and remain committed to advancing with urgency and purpose."

Generated Q1'25 total revenue, net of $1.0 billion and adjusted revenue of $1.3 billion. Adjusted revenue came in at the high end of our guidance rangeReported Q1'25 GAAP net loss of $212 million, or $0.08 GAAP diluted loss per share and adjusted net income of $80 million, or $0.04 adjusted diluted earnings per shareDelivered Q1'25 adjusted EBITDA of $169 million

DETROIT, May 8, 2025 /PRNewswire/ -- Rocket Companies, Inc. (NYSE: RKT) ("Rocket Companies" or the "Company"), the Detroit-based fintech platform company including mortgage, real estate, title and personal finance businesses, today announced results for the first quarter ended March 31, 2025.

MILWAUKEE, May 8, 2025 /PRNewswire/ -- At WEC Energy Group's (NYSE: WEC) annual meeting of stockholders today, Gale Klappa, chairman of the board, and Scott Lauber, president and CEO, highlighted another strong year on virtually every meaningful measure — from customer satisfaction, to financial performance, to steady execution of the company's capital plan. They also emphasized that it was a year of growth and dedication to the company's mission of delivering affordable, reliable and clean energy to millions of customers across the Midwest.

-- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET --

NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates.

Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right ("CVR") upon the achievement of a regulatory milestone, for a total equity value of up to approximately $1.7 billion; Expected to be completed in the second half of 2025, subject to customary closing conditions

Positive topline data from the completed fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) study of farabursen (RGLS8429) for the treatment of autosomal dominant polycystic kidney disease (ADPKD)

- BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment -

- Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) -

- Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 -

CARLSBAD, Calif., May 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress.

On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter

Positive topline del-zota data further supports first BLA submission at year end 2025 – continues to highlight reproducibility and consistency across three late-stage clinical trials for DMD44, DM1 and FSHD

 Executing on global commercial infrastructure development and on track with preparations for first potential commercial launch in U.S. in 2026